CLINICAL TRIALS PROFILE FOR DRISDOL

All Clinical Trials for DRISDOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00882401 ↗	Vitamin D, Chronic Kidney Disease (CKD) and the Microcirculation	Completed	Barts & The London NHS Trust	Phase 4	2009-04-01	Overall research aims: This study will examine the effect of vitamin D supplementation on the function of the endothelium and microcirculation of patients with chronic kidney disease and vitamin D deficiency. Hypothesis: Vitamin D therapy in patients with CKD and concomitant vitamin D deficiency will improve endothelial, and therefore microcirculatory function, reduce levels of oxidative stress and thus reduce the risk of future CVS events in this population.
NCT01004354 ↗	Vitamin D Supplementation in Psychiatric Illnesses	Completed	University of Massachusetts, Worcester	N/A	2009-06-01	Children and adolescents with psychiatric illnesses who are treated with medications called second generation antipsychotic agents (SGA) often gain excessive weight during their treatment with these medications. This weight gain may result in the development of features of the metabolic syndrome or frank diabetes mellitus. There is no consensus on the best way to prevent these complications. The investigators' hypothesis is that daily vitamin D supplementation in these patients will result in decreased levels of the markers of metabolic syndrome with associated reduction in waist circumference.
NCT01153243 ↗	Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes	Unknown status	Rush University	Phase 4	2007-04-01	Recent clinical trials in non diabetics showed that vitamin D supplementation markedly reduced serum levels of C-reactive protein (CRP), interleukin-6, and tissue matrix metallo-proteinases. Our study objective is to evaluate if administration of vitamin D in African Americans with hypovitaminosis D and DM Type 2 decreases serum levels of inflammatory/thrombotic markers such as CRP: Highly Sensitive C Reactive Protein.
NCT01153243 ↗	Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes	Unknown status	John H. Stroger Hospital	Phase 4	2007-04-01	Recent clinical trials in non diabetics showed that vitamin D supplementation markedly reduced serum levels of C-reactive protein (CRP), interleukin-6, and tissue matrix metallo-proteinases. Our study objective is to evaluate if administration of vitamin D in African Americans with hypovitaminosis D and DM Type 2 decreases serum levels of inflammatory/thrombotic markers such as CRP: Highly Sensitive C Reactive Protein.
NCT01312441 ↗	Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D	Terminated	Hortense & Louis Rubin Dialysis Center	Phase 4	2011-01-01	The prevalence of vitamin D deficiency increases as kidney function declines. As a result, many hemodialysis patients often have low levels of vitamin D. Recent evidence has shown that vitamin D supplementation may improve many aspects of poor health such as heart disease and inflammatory markers. The objectives of this study are to determine how supplementing dialysis patients with ergocalciferol increases vitamin D levels, how long vitamin D levels can be maintained after a 6 month treatment course, and to examine the effect of ergocalciferol on biomarkers of inflammation and vascular health.
NCT01312441 ↗	Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D	Terminated	Satellite Healthcare	Phase 4	2011-01-01	The prevalence of vitamin D deficiency increases as kidney function declines. As a result, many hemodialysis patients often have low levels of vitamin D. Recent evidence has shown that vitamin D supplementation may improve many aspects of poor health such as heart disease and inflammatory markers. The objectives of this study are to determine how supplementing dialysis patients with ergocalciferol increases vitamin D levels, how long vitamin D levels can be maintained after a 6 month treatment course, and to examine the effect of ergocalciferol on biomarkers of inflammation and vascular health.
NCT01312441 ↗	Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D	Terminated	VA Office of Research and Development	Phase 4	2011-01-01	The prevalence of vitamin D deficiency increases as kidney function declines. As a result, many hemodialysis patients often have low levels of vitamin D. Recent evidence has shown that vitamin D supplementation may improve many aspects of poor health such as heart disease and inflammatory markers. The objectives of this study are to determine how supplementing dialysis patients with ergocalciferol increases vitamin D levels, how long vitamin D levels can be maintained after a 6 month treatment course, and to examine the effect of ergocalciferol on biomarkers of inflammation and vascular health.

Clinical Trial Conditions for DRISDOL

Condition Name

Condition Name for DRISDOL
Intervention	Trials
Vitamin D Deficiency	4
Schizophrenia	1
Chronic Kidney Disease	1
Diabetes	1

Condition MeSH

Condition MeSH for DRISDOL
Intervention	Trials
Vitamin D Deficiency	4
Renal Insufficiency	1
Renal Insufficiency, Chronic	1
Kidney Failure, Chronic	1

Clinical Trial Locations for DRISDOL

Trials by Country

Trials by Country for DRISDOL
Location	Trials
United States	3
United Kingdom	1

Trials by US State

Trials by US State for DRISDOL
Location	Trials
North Carolina	1
New York	1
Massachusetts	1

Clinical Trial Progress for DRISDOL

Clinical Trial Phase

Clinical Trial Phase for DRISDOL
Clinical Trial Phase	Trials
Phase 4	3
N/A	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for DRISDOL
Clinical Trial Phase	Trials
Completed	3
Terminated	1
Unknown status	1

Clinical Trial Sponsors for DRISDOL

Sponsor Name

Sponsor Name for DRISDOL
Sponsor	Trials
Albany College of Pharmacy and Health Sciences	1
Wake Forest University Health Sciences	1
Barts & The London NHS Trust	1

Sponsor Type

Sponsor Type for DRISDOL
Sponsor	Trials
Other	8
U.S. Fed	1